<DOC>
	<DOCNO>NCT01433523</DOCNO>
	<brief_summary>The purpose trial investigate treatment house dust mite allergen immunotherapy tablet reduce risk asthma exacerbation subject house dust mite induce asthma .</brief_summary>
	<brief_title>House Dust Mite Treatment Asthma . The MITRA Trial House Dust Mite Treatment Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Key A clinical relevant history consistent house dust mite induce asthma least 1 year prior trial entry . Use appropriate amount inhale corticosteroid control asthma symptom . Documented reversible airway obstruction . Suitable level asthma control . FEV1 ≥ 70 % predict value . Positive Skin Prick Test response Der pte and/or Der far . Positive specific IgE Der pte and/or Der far ( ≥ IgE Class 2 ; ≥ 0.70 KU/L ) . Key A clinical history persistent allergic asthma rhinitis cause allergen subject regularly expose sensitise ( except house dust mite ) . A clinical history intermittent allergic asthma rhinitis seasonal allergen cause symptom period October March . Any clinically relevant chronic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HDM</keyword>
	<keyword>AIT</keyword>
	<keyword>asthma</keyword>
	<keyword>asthma exacerbation</keyword>
	<keyword>House dust mite induce asthma</keyword>
</DOC>